Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912237053> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2912237053 abstract "Background: Triple negative breast cancer (TNBC) is a biologically distinct subtype with high risk of early relapse, particularly for patients who do not achieve a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC), with an event free survival of Methods: Eligible pts are aged ≥18 years, with ER, PR and HER2 negative operable tumors ≥ 1.0 cm after neoadjuvant taxane-based chemotherapy. Approximately 160 patients will be randomized to one of two arms: standard-of-care breast surgery (control arm) or ipi/nivo/cryo followed by standard-of-care breast surgery (intervention arm). Subjects randomized to the intervention arm will undergo percutaneous, ultrasound- (or MRI-) guided cryoablation with concurrent research core biopsy 7-10 days prior to surgery, and will receive a pre-operative infusion with ipilimumab at the dose of 1mg/kg IV, and nivolumab 240mg flat dose IV (1 to 5 days prior to cryoablation). After surgery, patients will receive three additional doses of nivolumab 240mg flat dose IV Q2 weeks. Adjuvant capecitabine is recommended for all participants and will be administered per standard-of-care at the treating physician9s discretion. Patients will be stratified by prior platinum administration, prior anthracycline administration, and clinical nodal status (positive versus negative) at enrollment. The primary endpoint is 3-year Event Free Survival (EFS). Secondary end points include Invasive Disease-Free Survival (IDFS), Distant Disease-Free Survival (DDFS), overall survival (OS) and safety. Exploratory correlative studies will be performed on tumor and serum to characterize the immunologic impact of the intervention and to explore predictors of efficacy and toxicity. Citation Format: McArthur HL, Comen EA, Solomon S, Rodine M, DiLauro Abaya C, Leal JHS, Patil S, Norton L. A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard peri-operative care in women with residual triple negative early stage/resectable breast cancer after standard-of-care neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-06-05." @default.
- W2912237053 created "2019-02-21" @default.
- W2912237053 creator A5004654247 @default.
- W2912237053 creator A5021419901 @default.
- W2912237053 creator A5027846987 @default.
- W2912237053 creator A5031784115 @default.
- W2912237053 creator A5034624795 @default.
- W2912237053 creator A5046489359 @default.
- W2912237053 creator A5048199418 @default.
- W2912237053 creator A5050826635 @default.
- W2912237053 date "2019-02-15" @default.
- W2912237053 modified "2023-09-26" @default.
- W2912237053 title "Abstract OT2-06-05: A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard peri-operative care in women with residual triple negative early stage/resectable breast cancer after standard-of-care neoadjuvant chemotherapy" @default.
- W2912237053 doi "https://doi.org/10.1158/1538-7445.sabcs18-ot2-06-05" @default.
- W2912237053 hasPublicationYear "2019" @default.
- W2912237053 type Work @default.
- W2912237053 sameAs 2912237053 @default.
- W2912237053 citedByCount "2" @default.
- W2912237053 countsByYear W29122370532019 @default.
- W2912237053 countsByYear W29122370532020 @default.
- W2912237053 crossrefType "proceedings-article" @default.
- W2912237053 hasAuthorship W2912237053A5004654247 @default.
- W2912237053 hasAuthorship W2912237053A5021419901 @default.
- W2912237053 hasAuthorship W2912237053A5027846987 @default.
- W2912237053 hasAuthorship W2912237053A5031784115 @default.
- W2912237053 hasAuthorship W2912237053A5034624795 @default.
- W2912237053 hasAuthorship W2912237053A5046489359 @default.
- W2912237053 hasAuthorship W2912237053A5048199418 @default.
- W2912237053 hasAuthorship W2912237053A5050826635 @default.
- W2912237053 hasConcept C121608353 @default.
- W2912237053 hasConcept C126322002 @default.
- W2912237053 hasConcept C141071460 @default.
- W2912237053 hasConcept C143998085 @default.
- W2912237053 hasConcept C146357865 @default.
- W2912237053 hasConcept C151730666 @default.
- W2912237053 hasConcept C168563851 @default.
- W2912237053 hasConcept C203092338 @default.
- W2912237053 hasConcept C2776802502 @default.
- W2912237053 hasConcept C2777511904 @default.
- W2912237053 hasConcept C2777628079 @default.
- W2912237053 hasConcept C2777701055 @default.
- W2912237053 hasConcept C2778292576 @default.
- W2912237053 hasConcept C2778902805 @default.
- W2912237053 hasConcept C2780030458 @default.
- W2912237053 hasConcept C2780110267 @default.
- W2912237053 hasConcept C2781190966 @default.
- W2912237053 hasConcept C2781433595 @default.
- W2912237053 hasConcept C530470458 @default.
- W2912237053 hasConcept C71924100 @default.
- W2912237053 hasConcept C86803240 @default.
- W2912237053 hasConceptScore W2912237053C121608353 @default.
- W2912237053 hasConceptScore W2912237053C126322002 @default.
- W2912237053 hasConceptScore W2912237053C141071460 @default.
- W2912237053 hasConceptScore W2912237053C143998085 @default.
- W2912237053 hasConceptScore W2912237053C146357865 @default.
- W2912237053 hasConceptScore W2912237053C151730666 @default.
- W2912237053 hasConceptScore W2912237053C168563851 @default.
- W2912237053 hasConceptScore W2912237053C203092338 @default.
- W2912237053 hasConceptScore W2912237053C2776802502 @default.
- W2912237053 hasConceptScore W2912237053C2777511904 @default.
- W2912237053 hasConceptScore W2912237053C2777628079 @default.
- W2912237053 hasConceptScore W2912237053C2777701055 @default.
- W2912237053 hasConceptScore W2912237053C2778292576 @default.
- W2912237053 hasConceptScore W2912237053C2778902805 @default.
- W2912237053 hasConceptScore W2912237053C2780030458 @default.
- W2912237053 hasConceptScore W2912237053C2780110267 @default.
- W2912237053 hasConceptScore W2912237053C2781190966 @default.
- W2912237053 hasConceptScore W2912237053C2781433595 @default.
- W2912237053 hasConceptScore W2912237053C530470458 @default.
- W2912237053 hasConceptScore W2912237053C71924100 @default.
- W2912237053 hasConceptScore W2912237053C86803240 @default.
- W2912237053 hasLocation W29122370531 @default.
- W2912237053 hasOpenAccess W2912237053 @default.
- W2912237053 hasPrimaryLocation W29122370531 @default.
- W2912237053 isParatext "false" @default.
- W2912237053 isRetracted "false" @default.
- W2912237053 magId "2912237053" @default.
- W2912237053 workType "article" @default.